Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy

Efavirenz is the preferred nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line antiretroviral therapy (ART) regimens in low- and middle-income countries, where the prevalence of diabetes is increasing. Randomized control trials have shown mild increases in plasma glucose in participa...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamchand, Sumanth, Leisegang, Rory, Schomaker, Michael, Maartens, Gary, Walters, Lourens, Hislop, Michael, Dave, Joel A., Levitt, Naomi S., Cohen, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4850
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782850/
https://www.ncbi.nlm.nih.gov/pubmed/26945366
http://dx.doi.org/10.1097/MD.0000000000002844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782850/
https://www.ncbi.nlm.nih.gov/pubmed/26945366
http://dx.doi.org/10.1097/MD.0000000000002844

Ejemplares similares